Agenus Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $42.9K | $22.6M | $24.8M | $7.0M | $3.0M | $16.0M | $2.8M | $3.4M |
| Product revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $52.5K |
| Grant revenue | $168 | $32.4K | $24.1K | $504.2K | $0 | $0 | $0 | $424.7K |
| Service revenue | $0 | $147.5K | $0 | $0 | $1.4M | $1.5M | $0 | $0 |
| Research and development revenue (legacy pre-ASC606 aggregate) | $0 | $22.4M | $24.8M | $6.5M | $1.6M | $14.5M | $2.8M | $2.9M |
| License fees and milestones | $25.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Royalty sales milestone | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development services | $14.6K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Clinical product revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Manufacturing services | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other services | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Recognition of deferred R&D revenue | $3.1K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Non-cash royalty revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | $0 | $536.1K | $672.0K | $0 | $122.9K |
| Gross Profit | — | — | — | $7.0M | $2.5M | $15.3M | $2.8M | $3.2M |
| Gross Margin | — | — | — | 100.0% | 82.4% | 95.8% | 100.0% | 96.3% |
| Operating Expenses | ||||||||
| Research & Development | $116.1M | $95.0M | $70.4M | $22.3M | $13.0M | $10.6M | $11.0M | $12.9M |
| SG&A Expense | $33.7M | $33.1M | $28.4M | $21.2M | $14.5M | $11.5M | $10.8M | $12.1M |
| Operating Income | $-103.8M | $-107.5M | $-80.7M | $-43.3M | $-25.0M | $-6.7M | $-19.1M | $-21.8M |
| Operating Margin | -242,090.2% | -476.1% | -325.2% | -620.9% | -820.3% | -42.2% | -692.6% | -647.5% |
| Interest Expense | $31.3M | $19.4M | $4.3M | $1.3M | $2.4M | $4.7M | $4.2M | $4.9M |
| Pretax Income | $-120.7M | $-127.0M | $-93.3M | $-42.5M | $-30.1M | — | — | — |
| Income Tax Expense | $0 | $0 | $-5.4M | $0 | $0 | $0 | $0 | — |
| Net Income | $-120.7M | $-127.0M | $-87.9M | $-42.5M | $-30.1M | $-11.3M | $-23.3M | $-21.9M |
| Net Margin | -281,485.4% | -562.6% | -354.1% | -608.9% | -987.5% | -71.0% | -844.6% | -652.0% |
| EPS (Basic) | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.02 | $-0.01 | $-0.02 | $-0.02 |
| EPS (Diluted) | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.02 | $-0.01 | $-0.02 | $-0.02 |
| Shares Outstanding (Basic) | 6.10B | 5.36B | 4.39B | 3.85B | 1.57B | 1.39B | — | — |
| Shares Outstanding (Diluted) | 6.10B | 5.36B | 4.39B | 3.85B | 1.57B | 1.39B | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |